2.46
Fortress Biotech Inc stock is traded at $2.46, with a volume of 316.42K.
It is up +3.36% in the last 24 hours and down -5.38% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.38
Open:
$2.41
24h Volume:
316.42K
Relative Volume:
0.45
Market Cap:
$81.72M
Revenue:
$63.26M
Net Income/Loss:
$-32.92M
P/E Ratio:
-20.59
EPS:
-0.1195
Net Cash Flow:
$-71.34M
1W Performance:
+9.82%
1M Performance:
-5.38%
6M Performance:
-0.81%
1Y Performance:
+38.20%
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
FBIO
Fortress Biotech Inc
|
2.46 | 81.72M | 63.26M | -32.92M | -71.34M | -0.1195 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - marketscreener.com
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
MSN Money - MSN
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Executive pay, ownership and auditor up for vote at Fortress Biotech (NASDAQ: FBIO) - Stock Titan
Why Is Fortress Biotech Stock Falling Today? - MSN
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS missInvestor Call - Cổng thông tin điện tử tỉnh Lào Cai
Fortress (FBIOP) Investment Case | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Rosacea drug Emrosi expands access to over 150 million U.S. lives - Stock Titan
(FBIOP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Is the pipeline strength now the real test for investors? - AD HOC NEWS
FBIO | Fortress Biotech, Inc. Insider Trading - Quiver Quantitative
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Is Fortress Biotech (FBIO) Stock a Long-Term Buy? (Trend Weakens) 2026-04-16Value Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Aug Spikes: Is Fortress Biotech Inc part of any ETFPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Is Fortress Biotech (FBIO) Stock Cheap at Current Price | Price at $2.44, Up 3.62%Debt Free Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Growth Value: How does Fortress Biotech Inc score in quality rankingsDay Trade & High Conviction Investment Ideas - baoquankhu1.vn
Sectors Review: Should value investors consider Fortress Biotech Inc2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Liquidity Mapping Around (FBIOP) Price Events - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Maintains Target Price $4.5 - Moomoo
Institution Moves: Does Fortress Biotech Inc stock benefit from AI growth2026 Volume Leaders & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Is Fortress Biotech (FBIO) Stock better than industry peers | Price at $2.35, Down 6.37%Fast Rising Picks - Xã Vĩnh Công
Is Fortress (FBIOP) Stock Discounted Now | Price at $13.62, Up 0.26%Fundamental Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - Barchart.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView — Track All Markets
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes - GlobeNewswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):